Therapeutic drug monitoring

The drug adalimumab is used very successfully in the treatment of various inflammatory diseases. Yet in some patients, the efficacy of this drug decreases over time. We explain why this is so and [...]

May is completely characterized by intestinal health: first Digestive Disease Week, now World IBD Day. The aim of the IBD action day is to raise awareness about inflammatory bowel diseases [...]

Therapeutic drug monitoring (TDM) is used to measure the concentration of an active ingredient in the patient’s blood. Using this information, physicians can adjust the dose individually to the [...]

So-called TNFα blockers are commonly used in the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Therapeutic drug monitoring improves the effect of [...]

Chronic inflammatory bowel disease (IBD) is characterized by recurring and often ongoing flares. The most common forms of IBD are Crohns disease and Ulcerative colitis.

TNFalpha blocker are biologic agents, which are used for the treatment of inflammatory diseases such as Ulcerative Colitis, Crohns disease and Rheumatoid Arthritis. Infliximab as well as [...]

Molander et al. investigated if concentrations of fecal calprotectin can be used for predicting relaps after stopping TNFα blocking therapy in patients with Ulcerative Colitis and Morbus Crohn.

Study about first randomized, controlled testing shows that clinical treatment decisions based on therapeutic drug monitoring (TDM) is superior to dose-intensification strategy.

Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars were equally well quantified as the original infliximab (IFX) drug in their clinically validated infliximab assay.

RIDASCREEN® IFX Monitoring is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, anti-TNFα) in human serum and plasma.